Your trusted destination for CME, CPD & Medical Education across the Middle East.
Isomorphic Labs
Max Jaderberg is a British artificial intelligence researcher, computer scientist, and technology entrepreneur recognized for his contributions to deep learning, computer vision, reinforcement learning, and AI-driven drug discovery. His work focuses on developing advanced machine learning systems capable of solving complex scientific and computational problems.
He completed his undergraduate degree in Engineering Science at the University of Oxford and subsequently earned his PhD from Oxford's Visual Geometry Group. His doctoral research focused on computer vision, image recognition, text recognition, and deep learning algorithms for image understanding. His academic work contributed to advances in neural networks and computer vision, including the development of Spatial Transformer Networks.
Jaderberg began his entrepreneurial career by co-founding Vision Factory, a company specializing in deep-learning-based image recognition technology. The company was acquired by Google in 2014 and became part of DeepMind, where he continued his research career.
At Google DeepMind, Jaderberg led the Open-Ended Learning research team. He contributed to significant developments in reinforcement learning and artificial intelligence, including research associated with AlphaStar, Capture the Flag, and population-based training. His work explored how AI systems could learn complex behaviours through large-scale training, simulation, and interaction.
In 2021, he joined the founding team of Isomorphic Labs, a digital biology company established to transform drug discovery through artificial intelligence. He initially served as Chief AI Officer, leading the development and application of AI models for drug design, including work associated with AlphaFold 3.
Effective January 1, 2026, Jaderberg became President of Isomorphic Labs. In this role, he leads the company's operations and strategic development alongside founder and CEO Demis Hassabis. His current work focuses on advancing AI-powered drug-design technologies, building scientific partnerships, and translating computational breakthroughs into potential medicines.

dmg events
dmg events